Advertisement
- United States
- /
- Pharma
- /
- NasdaqCM:LEXX
Lexaria Bioscience Second Quarter 2025 Earnings: Beats Expectations
Lexaria Bioscience (NASDAQ:LEXX) Second Quarter 2025 Results
Key Financial Results
- Net loss: US$2.71m (loss widened by 318% from 2Q 2024).
- US$0.15 loss per share (further deteriorated from US$0.06 loss in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Lexaria Bioscience Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 91%. Earnings per share (EPS) also surpassed analyst estimates by 8.2%.
Looking ahead, revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Pharmaceuticals industry in the US.
Performance of the American Pharmaceuticals industry.
The company's shares are up 7.5% from a week ago.
Risk Analysis
Be aware that Lexaria Bioscience is showing 6 warning signs in our investment analysis and 3 of those can't be ignored...
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:LEXX
Flawless balance sheet with high growth potential.
Market Insights
Advertisement
Weekly Picks
AL
AlexLovell on Rocket Lab ·
Early mover in a fast growing industry. Likely to experience share price volatility as they scale
Fair Value:US$16.25367.6% overvalued
68 followersusers have followed this narrative
1 commentusers have commented on this narrative
18 likesusers have liked this narrative
AG
Agricola on Excellon Resources ·
A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).
Fair Value:CA$31.898.3% undervalued
65 followersusers have followed this narrative
10 commentsusers have commented on this narrative
19 likesusers have liked this narrative
FU
FundamentallySarcastic on Credit Corp Group ·
Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08
Fair Value:AU$12.6410.4% overvalued
11 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
Recently Updated Narratives
BO
BonSquid88 on Micron Technology ·
Micron Technology will experience a robust 16.5% revenue growth
Fair Value:US$40021.1% undervalued
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
MA
MarketMuse on Amazon.com ·
Amazon will rebound as AI investments start paying off by late 2026
Fair Value:US$45049.7% undervalued
45 followersusers have followed this narrative
2 commentsusers have commented on this narrative
0 likesusers have liked this narrative
RO
Robbo on Harvey Norman Holdings ·
Inside Harvey Norman: Asset-Heavy Retail in an Online World
Fair Value:AU$5.8419.5% overvalued
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Popular Narratives
AG
Agricola on Excellon Resources ·
A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).
Fair Value:CA$31.898.3% undervalued
65 followersusers have followed this narrative
10 commentsusers have commented on this narrative
19 likesusers have liked this narrative
AL
AlexLovell on Rocket Lab ·
Early mover in a fast growing industry. Likely to experience share price volatility as they scale
Fair Value:US$16.25367.6% overvalued
68 followersusers have followed this narrative
1 commentusers have commented on this narrative
18 likesusers have liked this narrative
AN
AnalystConsensusTarget on NVIDIA ·
NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
Fair Value:US$253.0225.4% undervalued
1011 followersusers have followed this narrative
6 commentsusers have commented on this narrative
28 likesusers have liked this narrative
Trending Discussion
ST
StevenM on Excellon Resources ·
Interesting analysis, but the price trajectory assumed for the baseline metals is problematic. These assumptions form the foundation for the entire case, and when compared against historical pricing, don’t appear to be grounded in any reasonable precedent. Even accounting for past commodity super-cycles, inflationary periods, or supply constraints, the forecasted pricing for gold, silver, zinc, and lead are well outside what history would suggest is plausible over comparable timeframes. That creates a fragile premise as the conclusions are driven by aggressive inputs rather than underlying market behavior that is realistic. The analysis would be materially stronger if the price assumptions were anchored to historical ranges and prior cycle peaks, with explicit rationale where the model intentionally departs from those patterns. As it stands, the trajectory feels more aspirational than analytical.
1
|1
